Caplin Steriles bags USFDA nod for Etomidate injection
Etomidate is a general anesthetic, used for the induction of general anesthesia and for the supplementation of subpotent anesthetic agents.
Chennai: Caplin Point Laboratories Limited today announced that Caplin Steriles Limited, a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Etomidate injection USP, 20 mg/10 ml (2 mg/ml) and 40 mg/20 ml (2 mg/ml) Single-dose vial presentations.
The product is a generic therapeutic equivalent version of (RLD), AMIDATE (Etomidate) Injection, of HOSPIRA INC.
According to IQVIA (IMS Health), Etomidate injection USP had US sales data of approximately $9 million for the 12- month period ending Oct 2020. Caplin Steriles Limited has developed and filed 19 ANDAs on its own and with partners, with 11 approvals so far.
Etomidate is a general anesthetic, used for the induction of general anesthesia and for the supplementation of subpotent anesthetic agents.
Mr.C.C.Paarthipan, Chairman of Caplin Point Laboratories Limited commented "We understand Etomidate injection has frequently been on the shortage list in the US, which is probably the reason why we received this approval within 6 months. We hope to launch this product within a short period in the US".
The Company is also working on a portfolio of 35 simple and complex Injectable and Ophthalmic products, to be filed over the next 4 years, with an addressable market size of USD 2.1 Billion.
Read also: Caplin Steriles, Xellia Pharma ink distribution pact for 5 injectables in US
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.